Selected research
Industry Research
Injectable Ketamine Industry Research Report 2026
Market perspective
The global Injectable Ketamine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Injectable Ketamine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Injectable Ketamine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Injectable Ketamine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Injectable Ketamine include Anhui Wanhe Pharmaceutical, Pfizer, Hengrui, Troikaa Parenterals, Taj Pharmaceuticals, Supriya Lifesciences, Sun Pharmaceuticals, Seqens and Samarth Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Injectable Ketamine market in terms of revenue (US$ million) and, where applicable, sales volume (Kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Injectable Ketamine Market by Company
Anhui Wanhe Pharmaceutical
Pfizer
Hengrui
Troikaa Parenterals
Taj Pharmaceuticals
Supriya Lifesciences
Sun Pharmaceuticals
Seqens
Samarth Pharma
Neon Laboratories
Ketalar
Hameln Pharma ltd
Greenco Biologicals
BNM Organics
Injectable Ketamine Segment by Type
Standard Ketamine
Low-Dose Ketamine
High-Dose Ketamine
Injectable Ketamine Segment by Application
Mental Health Treatment
Pain Management
Anesthetic Use
Injectable Ketamine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Injectable Ketamine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Injectable Ketamine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Injectable Ketamine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Injectable Ketamine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Injectable Ketamine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Injectable Ketamine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Standard Ketamine
- Low-Dose Ketamine
- High-Dose Ketamine
Applications
- Mental Health Treatment
- Pain Management
- Anesthetic Use
Companies covered
- Anhui Wanhe Pharmaceutical
- Pfizer
- Hengrui
- Troikaa Parenterals
- Taj Pharmaceuticals
- Supriya Lifesciences
- Sun Pharmaceuticals
- Seqens
- Samarth Pharma
- Neon Laboratories
- Ketalar
- Hameln Pharma ltd
- Greenco Biologicals
- BNM Organics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Injectable Ketamine Market Size (2021-2032)
- 2.2.2 Global Injectable Ketamine Sales (2021-2032)
- 2.2.3 Global Injectable Ketamine Market Average Price (2021-2032)
- 2.3 Injectable Ketamine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Standard Ketamine
- 2.3.3 Low-Dose Ketamine
- 2.3.4 High-Dose Ketamine
- 2.4 Injectable Ketamine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Mental Health Treatment
- 2.4.3 Pain Management
- 2.4.4 Anesthetic Use
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Injectable Ketamine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Injectable Ketamine Sales (Kg) of Manufacturers (2021-2026)
- 3.3 Global Injectable Ketamine Revenue of Manufacturers (2021-2026)
- 3.4 Global Injectable Ketamine Average Price by Manufacturers (2021-2026)
- 3.5 Global Injectable Ketamine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Injectable Ketamine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Injectable Ketamine, Product Type & Application
- 3.8 Global Manufacturers of Injectable Ketamine, Established Date
- 3.9 Global Injectable Ketamine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Anhui Wanhe Pharmaceutical
- 4.1.1 Anhui Wanhe Pharmaceutical Company Information
- 4.1.2 Anhui Wanhe Pharmaceutical Business Overview
- 4.1.3 Anhui Wanhe Pharmaceutical Injectable Ketamine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Anhui Wanhe Pharmaceutical Injectable Ketamine Product Portfolio
- 4.1.5 Anhui Wanhe Pharmaceutical Recent Developments
- 4.2 Pfizer
- 4.2.1 Pfizer Company Information
- 4.2.2 Pfizer Business Overview
- 4.2.3 Pfizer Injectable Ketamine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Pfizer Injectable Ketamine Product Portfolio
- 4.2.5 Pfizer Recent Developments
- 4.3 Hengrui
- 4.3.1 Hengrui Company Information
- 4.3.2 Hengrui Business Overview
- 4.3.3 Hengrui Injectable Ketamine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Hengrui Injectable Ketamine Product Portfolio
- 4.3.5 Hengrui Recent Developments
- 4.4 Troikaa Parenterals
- 4.4.1 Troikaa Parenterals Company Information
- 4.4.2 Troikaa Parenterals Business Overview
- 4.4.3 Troikaa Parenterals Injectable Ketamine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Troikaa Parenterals Injectable Ketamine Product Portfolio
- 4.4.5 Troikaa Parenterals Recent Developments
- 4.5 Taj Pharmaceuticals
- 4.5.1 Taj Pharmaceuticals Company Information
- 4.5.2 Taj Pharmaceuticals Business Overview
- 4.5.3 Taj Pharmaceuticals Injectable Ketamine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Taj Pharmaceuticals Injectable Ketamine Product Portfolio
- 4.5.5 Taj Pharmaceuticals Recent Developments
- 4.6 Supriya Lifesciences
- 4.6.1 Supriya Lifesciences Company Information
- 4.6.2 Supriya Lifesciences Business Overview
- 4.6.3 Supriya Lifesciences Injectable Ketamine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Supriya Lifesciences Injectable Ketamine Product Portfolio
- 4.6.5 Supriya Lifesciences Recent Developments
- 4.7 Sun Pharmaceuticals
- 4.7.1 Sun Pharmaceuticals Company Information
- 4.7.2 Sun Pharmaceuticals Business Overview
- 4.7.3 Sun Pharmaceuticals Injectable Ketamine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sun Pharmaceuticals Injectable Ketamine Product Portfolio
- 4.7.5 Sun Pharmaceuticals Recent Developments
- 4.8 Seqens
- 4.8.1 Seqens Company Information
- 4.8.2 Seqens Business Overview
- 4.8.3 Seqens Injectable Ketamine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Seqens Injectable Ketamine Product Portfolio
- 4.8.5 Seqens Recent Developments
- 4.9 Samarth Pharma
- 4.9.1 Samarth Pharma Company Information
- 4.9.2 Samarth Pharma Business Overview
- 4.9.3 Samarth Pharma Injectable Ketamine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Samarth Pharma Injectable Ketamine Product Portfolio
- 4.9.5 Samarth Pharma Recent Developments
- 4.10 Neon Laboratories
- 4.10.1 Neon Laboratories Company Information
- 4.10.2 Neon Laboratories Business Overview
- 4.10.3 Neon Laboratories Injectable Ketamine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Neon Laboratories Injectable Ketamine Product Portfolio
- 4.10.5 Neon Laboratories Recent Developments
- 4.11 Ketalar
- 4.11.1 Ketalar Company Information
- 4.11.2 Ketalar Business Overview
- 4.11.3 Ketalar Injectable Ketamine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Ketalar Injectable Ketamine Product Portfolio
- 4.11.5 Ketalar Recent Developments
- 4.12 Hameln Pharma ltd
- 4.12.1 Hameln Pharma ltd Company Information
- 4.12.2 Hameln Pharma ltd Business Overview
- 4.12.3 Hameln Pharma ltd Injectable Ketamine Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Hameln Pharma ltd Injectable Ketamine Product Portfolio
- 4.12.5 Hameln Pharma ltd Recent Developments
- 4.13 Greenco Biologicals
- 4.13.1 Greenco Biologicals Company Information
- 4.13.2 Greenco Biologicals Business Overview
- 4.13.3 Greenco Biologicals Injectable Ketamine Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Greenco Biologicals Injectable Ketamine Product Portfolio
- 4.13.5 Greenco Biologicals Recent Developments
- 4.14 BNM Organics
- 4.14.1 BNM Organics Company Information
- 4.14.2 BNM Organics Business Overview
- 4.14.3 BNM Organics Injectable Ketamine Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 BNM Organics Injectable Ketamine Product Portfolio
- 4.14.5 BNM Organics Recent Developments
5 Global Injectable Ketamine Market Scenario by Region
- 5.1 Global Injectable Ketamine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Injectable Ketamine Sales by Region: 2021-2032
- 5.2.1 Global Injectable Ketamine Sales by Region: 2021-2026
- 5.2.2 Global Injectable Ketamine Sales by Region: 2027-2032
- 5.3 Global Injectable Ketamine Revenue by Region: 2021-2032
- 5.3.1 Global Injectable Ketamine Revenue by Region: 2021-2026
- 5.3.2 Global Injectable Ketamine Revenue by Region: 2027-2032
- 5.4 North America Injectable Ketamine Market Facts & Figures by Country
- 5.4.1 North America Injectable Ketamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Injectable Ketamine Sales by Country (2021-2032)
- 5.4.3 North America Injectable Ketamine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Injectable Ketamine Market Facts & Figures by Country
- 5.5.1 Europe Injectable Ketamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Injectable Ketamine Sales by Country (2021-2032)
- 5.5.3 Europe Injectable Ketamine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Injectable Ketamine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Injectable Ketamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Injectable Ketamine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Injectable Ketamine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Injectable Ketamine Market Facts & Figures by Country
- 5.7.1 South America Injectable Ketamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Injectable Ketamine Sales by Country (2021-2032)
- 5.7.3 South America Injectable Ketamine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Injectable Ketamine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Injectable Ketamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Injectable Ketamine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Injectable Ketamine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Injectable Ketamine Sales by Type (2021-2032)
- 6.1.1 Global Injectable Ketamine Sales by Type (2021-2032) & (Kg)
- 6.1.2 Global Injectable Ketamine Sales Market Share by Type (2021-2032)
- 6.2 Global Injectable Ketamine Revenue by Type (2021-2032)
- 6.2.1 Global Injectable Ketamine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Injectable Ketamine Revenue Market Share by Type (2021-2032)
- 6.3 Global Injectable Ketamine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Injectable Ketamine Sales by Application (2021-2032)
- 7.1.1 Global Injectable Ketamine Sales by Application (2021-2032) & (Kg)
- 7.1.2 Global Injectable Ketamine Sales Market Share by Application (2021-2032)
- 7.2 Global Injectable Ketamine Revenue by Application (2021-2032)
- 7.2.1 Global Injectable Ketamine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Injectable Ketamine Revenue Market Share by Application (2021-2032)
- 7.3 Global Injectable Ketamine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Injectable Ketamine Value Chain Analysis
- 8.1.1 Injectable Ketamine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Injectable Ketamine Production Mode & Process
- 8.2 Injectable Ketamine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Injectable Ketamine Distributors
- 8.2.3 Injectable Ketamine Customers
9 Global Injectable Ketamine Analyzing Market Dynamics
- 9.1 Injectable Ketamine Industry Trends
- 9.2 Injectable Ketamine Industry Drivers
- 9.3 Injectable Ketamine Industry Opportunities and Challenges
- 9.4 Injectable Ketamine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst